Retatrutide: sourcing and COA guide
Retatrutide is an investigational triple agonist targeting the GLP-1, GIP, and glucagon (GCGR) receptors. For laboratories evaluating emerging incretin-class reference compounds, the sourcing bar is high: identity, purity, and batch-level Certificates of Analysis must be verified before any research use.
Mechanism at a glance
Retatrutide is a synthetic peptide engineered as a balanced agonist at three incretin and glucagon-family receptors:
- GLP-1R — glucose-dependent insulinotropic activity.
- GIPR — potentiates insulin release and modulates adipocyte signaling.
- GCGR — glucagon receptor engagement associated with energy expenditure.
The triple-agonist profile is what distinguishes it from single-target GLP-1 references and dual GLP-1 / GIP agonists.
Purity and identity standards
HPLC purity
We require ≥ 98% HPLC purity, with a chromatogram showing a clean single peak and well-characterized impurity profile.
Mass confirmation
Mass spectrometry must match the theoretical monoisotopic mass of the retatrutide sequence within instrument tolerance.
Additional endotoxin and appearance testing is performed on every batch. Every unit shipped is traceable to a specific batch and its independent Certificate of Analysis.
What a good COA includes
- Compound name, sequence, and molecular formula
- HPLC purity chromatogram and numeric result
- Mass spectrometry identity confirmation
- Endotoxin result and appearance / solubility notes
- Independent third-party lab identifier and batch reference
For research use only
Retatrutide is supplied strictly for in-vitro laboratory research. It is not a drug, is not for human or veterinary use, and is not intended to diagnose, treat, cure, or prevent any disease.